Does Peptide Sciences sell retatrutide? Here's the law

Last updated 2026-07-25

Does Peptide Sciences sell retatrutide legally?

No. There is no legal pathway for any company, whatever it calls itself, to sell retatrutide for a person to inject. This isn't a judgment call about one specific vendor's paperwork. It's baked into three separate facts about retatrutide's regulatory status. First, retatrutide has never been approved by the FDA for any use. A search of Drugs@FDA, the agency's own database of approved drug products, returns nothing under the generic name retatrutide ^[1]. Second, it isn't on the 503A Bulks List, the short roster of substances a compounding pharmacy may legally use when a drug isn't otherwise commercially available ^[2]. Third, it has no USP or NF monograph and isn't a component of any approved drug, so even the fallback compounding routes don't apply to it ^[3]. Put those together and you get a simple answer: whatever a site calls its product, whether it's labeled "research use only" or something else, there is no lawful route to sell retatrutide as something a person takes. This article isn't about any single company's business practices. It's about explaining, plainly, why that's true for the whole category of vendors selling this compound online, and what a straight answer to "does Peptide Sciences sell retatrutide" actually requires you to understand about the law underneath the question.

Is retatrutide approved by the FDA for any use?

No. Retatrutide has zero FDA-approved indications as of this writing. Anyone searching Drugs@FDA, the agency's official database of every approved drug product, for the generic name "retatrutide" gets no results ^[1]. That matters more than it might sound. Under 21 U.S.C. 355, a new drug can't be introduced into interstate commerce without an approved application ^[4]. There's no carve-out for peptides, no carve-out for injectables sold with a disclaimer, and no carve-out for products marketed as "not for human consumption." If a substance hasn't cleared FDA review and been approved, moving it in commerce for people to use is the exact activity the statute exists to stop. Compare this to retatrutide's cousins. Semaglutide is approved and sold as Ozempic and Wegovy. Tirzepatide is approved as Mounjaro and Zepbound. Orforglipron, a newer oral incretin, was approved as Foundayo under NDA 220934 in six strengths ranging from 0.8 mg to 17.2 mg ^{[1] [5]}. All three have gone through the full approval process, with published safety data, manufacturing oversight, and prescribing information. Retatrutide has none of that. It's still an investigational compound, full stop.

Is retatrutide on the FDA's 503A Bulks List?

No, and this is worth spelling out because it's the specific legal mechanism that would let a compounding pharmacy use it, if it applied. The complete, final 503A Bulks List at 21 CFR 216.23 contains exactly six substances: Brilliant Blue G, cantharidin, diphenylcyclopropenone, N-acetyl-D-glucosamine, squaric acid dibutyl ester, and thymol iodide ^[2]. None of those is a peptide. Retatrutide is nowhere on that list. FDA also keeps a running public list of substances nominated for the 503A list, sorted into interim categories while they're under review ^[6]. Retatrutide doesn't appear there either, and it has never been nominated. For comparison, FDA's Pharmacy Compounding Advisory Committee met on 23 and 24 July 2026 specifically to weigh seven other peptides for the list: BPC-157, KPV, TB-500, MOTS-c, emideltide (DSIP), semax, and epitalon ^[7]. Retatrutide wasn't among them. Even if it had been nominated and even if that committee had voted favorably, that alone wouldn't create a compounding pathway. Advisory committee recommendations are non-binding. Actually adding a substance to the Bulks List requires full notice-and-comment rulemaking, a process that takes years, not a single meeting ^[7]. So "under review" and "legal to compound" are two very different things, and retatrutide is neither right now, it's simply absent from the whole process.

Why can't a compounding pharmacy just make retatrutide anyway?

Because Section 503A sets up a strict, three-step cascade for what a compounding pharmacy is allowed to use, and retatrutide fails all three steps. Under 21 U.S.C. 353a(b)(1)(A)(i), a bulk substance used in compounding must first comply with an applicable USP or NF monograph, if one exists ^[3]. Retatrutide has no such monograph. If no monograph exists, the substance can qualify as a component of an FDA-approved drug. Retatrutide isn't that either, since nothing containing it has been approved. Only if neither of those applies can a pharmacy fall back to the 503A Bulks List itself, and as covered above, retatrutide isn't there. Three chances, three failures. There's a second, entirely separate requirement that trips up gray-market retatrutide too. Section 503A also demands that any bulk drug substance come from a supplier registered under FD&C Act section 510, and that it arrive with a valid certificate of analysis ^[3]. Research-use-only material shipped from an unregistered overseas supplier fails this requirement regardless of anything else, even in the hypothetical world where the ingredient cascade problem didn't exist. There's genuinely no door left open here. If you're weighing whether to look at retatrutide peptide buy options online, this is the legal wall you're actually running into, not a technicality that a particular seller has found a way around.

Does a research-use-only label make retatrutide sales legal?

No, and FDA has said so directly. A disclaimer on a bottle or a website doesn't change what a product legally is if the seller's own marketing says otherwise. Under 21 CFR 201.128, a product's "intended use" is established by labeling claims, advertising, and statements made by the seller, not by a disclaimer buried in the fine print ^[8]. FDA applied exactly this reasoning in a March 2026 warning letter to Gram Peptides. The agency wrote that "despite such labelling, evidence from the company's website established that its products were intended to be drugs for human use," and the letter specifically cited retatrutide marketed on that site ^[9]. In other words, calling something "research use only" doesn't survive contact with a webpage that talks about weight loss, dosing, or how a customer should use the product on themselves. This is the general problem with the entire research-chemical retatrutide market, not a quirk of any one vendor. If a site's marketing copy reads like it's selling a treatment, that's what FDA treats it as, disclaimer or not.

What has retatrutide actually shown in clinical trials?

The trial data is genuinely strong, which is exactly why so many people are trying to get their hands on it early. In the phase 2 obesity trial published in the New England Journal of Medicine, the 12 mg dose of retatrutide produced a mean weight reduction of 24.2 percent at 48 weeks, compared with 2.1 percent for placebo ^[10]. That's a big number. It's larger than what's been reported for approved GLP-1 drugs at comparable trial durations, and it's the reason retatrutide gets so much attention despite being years from any possible approval. The trial, registered as NCT04881760 ("A Study of LY3437943 in Participants Who Have Obesity or Are Overweight"), used weekly subcutaneous injections across several dose arms ^[11]. LY3437943 is retatrutide's development code, the name it carried before anyone called it retatrutide. Retatrutide is a triple agonist, meaning it acts at three separate receptors: GIP, GLP-1, and glucagon. That's mechanistically different from semaglutide, which only hits GLP-1, and tirzepatide, which hits GIP and GLP-1 but not glucagon ^[10]. The drug hasn't stopped at phase 2. It has moved into later-phase registered trials, including NCT05929066 and NCT05882045, whose public records list enrollment criteria, comparator arms, and endpoints ^{[12] [13]}. There are also registered type 2 diabetes trials running alongside the obesity program, so the evidence base is broader than a single indication ^[11]. None of that changes the legal picture. Strong data in a trial is not the same thing as an approved, prescribable drug, and it's not a green light for anyone to source the compound outside that trial.

What dose did the retatrutide trials actually use?

The published phase 2 trial tested weekly subcutaneous injections across a range of doses, with the top studied dose at 12 mg producing the 24.2 percent weight loss figure at 48 weeks ^[10]. That's trial data, collected under a monitored protocol with a specific formulation, specific titration schedule, and clinical oversight at every step. It is not a dosing instruction for anyone to follow on their own. No doctor in the United States can lawfully prescribe retatrutide outside a registered clinical trial, because there's no approved product to prescribe. Reporting what a trial used is different from recommending it; the difference matters a lot when the compound in question hasn't been reviewed by FDA and isn't manufactured under any pharmaceutical quality standard outside that trial setting. If you want to understand how trial dosing schedules are typically structured, a retatrutide dosage chart breaks down what's been published, again as trial history, not as a protocol to copy.

What's the difference between the 503A and 503B bulks lists?

Both lists matter for the same reason: neither one includes retatrutide. Section 503A covers traditional compounding pharmacies making patient-specific prescriptions. Its Bulks List sits at 21 CFR 216.23 and has exactly six substances on it, none of them retatrutide ^[2]. Section 503B covers outsourcing facilities, which are larger operations that can compound in bulk without individual patient prescriptions, generally for hospitals and clinics. Their bulk substances list is a separate regulation, 21 CFR 216.24, and it likewise doesn't include retatrutide ^[14]. So there's no version of "compounding pharmacy" or "outsourcing facility" in the US legal system today that can put retatrutide into a product for a patient. Both doors are closed, and they're closed by different but parallel regulations.

Can I legally import retatrutide from overseas for personal use?

FDA's personal importation policy is narrow, and it does not create a workaround for buying an investigational drug like retatrutide online. The agency's guidance addresses limited circumstances, generally involving drugs for serious conditions without a US treatment alternative, and it is not a blanket permission slip for ordering unapproved compounds shipped from foreign suppliers ^[15]. Given that approved alternatives already exist for weight management (semaglutide, tirzepatide, and now orforglipron are all FDA-approved), the exception FDA sometimes allows for drugs with no domestic equivalent doesn't really apply here anyway ^{[1] [5]}. Ordering retatrutide from an overseas vendor, disclaimer or not, sits outside any lawful importation framework, and the product itself carries none of the manufacturing oversight or quality testing an approved drug requires.

What are the safety risks of unregulated retatrutide?

The honest answer is: nobody outside the clinical trial program has controlled safety data on unregulated retatrutide, because there isn't a controlled, quality-assured supply of it to study. The phase 2 trial data on efficacy and tolerability came from material manufactured and monitored under trial conditions, with dosing overseen by clinical staff ^[10]. Vendor material bought online has no equivalent oversight. That gap is exactly what the certificate-of-analysis and registered-establishment requirements in Section 503A are meant to prevent ^[3]. Skip those requirements and you're relying entirely on a seller's word for purity, concentration, and sterility, with no independent verification. For a deeper look at what's actually been reported in trials versus what's simply unknown for gray-market product, see retatrutide side effects.

What are the legal options if I want retatrutide's benefits now?

Right now, the only lawful way to access retatrutide at all is enrollment in one of its registered clinical trials, such as NCT04881760, NCT05929066, or NCT05882045, assuming you meet the enrollment criteria ^{[11] [12] [13]}. Outside that, retatrutide simply isn't available, and no legitimate clinician can write a prescription for it. For people who want an approved option with real safety data behind it today, the field isn't empty. Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are both approved with published trial results and years of post-market data ^[1]. Orforglipron, an oral GLP-1 agonist approved as Foundayo (NDA 220934) in strengths from 0.8 mg to 17.2 mg, is a newer approved option for people who'd rather avoid injections ^[5]. NIDDK's federal guidance on evidence-based weight management is a solid, neutral starting point for thinking through options with a clinician, without the noise of gray-market marketing . At Retatrutide Report, we track the trial data and legal status closely because readers deserve a straight answer about what's real and what isn't. Our position doesn't change based on how convincing a given vendor's website looks: no FDA approval and no compounding pathway means no lawful sale, for retatrutide specifically, today. For a general overview of where the trials stand and what's known about the molecule, see retatrutide peptide. If you're trying to understand injection prep steps discussed in trial contexts, how to reconstitute retatrutide covers what's been published, without suggesting anyone should be sourcing product outside a trial.

Frequently asked questions

Does Peptide Sciences sell retatrutide legally?

No vendor can legally sell retatrutide for human use, regardless of name or disclaimer. Retatrutide has no FDA approval ^[1] and isn't on the 503A Bulks List ^[2], so there's no lawful pathway for any company to sell it as something a person takes. A "research use only" label doesn't change that if the site's marketing implies human use ^[11][12].

Is retatrutide FDA approved?

No. A search of Drugs@FDA, the agency's database of approved drug products, returns no results under the generic name retatrutide. It remains an investigational compound studied in registered clinical trials, with no approved indication for weight loss, diabetes, or anything else.

Is retatrutide on the 503A Bulks List?

No. The final 503A Bulks List at 21 CFR 216.23 has exactly six substances: Brilliant Blue G, cantharidin, diphenylcyclopropenone, N-acetyl-D-glucosamine, squaric acid dibutyl ester, and thymol iodide. No peptide is on it, and retatrutide has never been nominated for the list either.

Can a compounding pharmacy legally make retatrutide?

No. Section 503A requires a bulk substance to have a USP/NF monograph, or be a component of an approved drug, or appear on the Bulks List. Retatrutide meets none of these three conditions, so no compounding pharmacy has a lawful basis to make it, regardless of demand.

Does a 'research use only' label make retatrutide sales legal?

No. FDA determines a product's intended use from labeling, advertising, and seller statements, not from a disclaimer. A March 2026 warning letter to Gram Peptides found the company's website established intended human use despite research-only labeling, and specifically named retatrutide sold on that site.

What did the retatrutide phase 2 trial actually find?

The published phase 2 trial found a mean weight reduction of 24.2 percent at the 12 mg dose at 48 weeks, versus 2.1 percent for placebo, using weekly subcutaneous injections. This was published in the New England Journal of Medicine and is registered on ClinicalTrials.gov as NCT04881760.

How is retatrutide different from semaglutide or tirzepatide?

Retatrutide is a triple agonist, acting at GIP, GLP-1, and glucagon receptors. Semaglutide acts only at GLP-1. Tirzepatide acts at GIP and GLP-1 but not glucagon. This broader receptor activity is part of why retatrutide's trial weight-loss results have drawn so much attention.

Can I import retatrutide from another country for personal use?

FDA's personal importation policy is narrow and generally applies to drugs for serious conditions with no US alternative. Since approved alternatives (semaglutide, tirzepatide, orforglipron) already exist for weight management, that exception doesn't apply here, and importing retatrutide sits outside any lawful framework.

Are there approved alternatives to retatrutide available now?

Yes. Semaglutide is approved as Ozempic and Wegovy, tirzepatide as Mounjaro and Zepbound, and orforglipron as Foundayo (NDA 220934, six strengths from 0.8 mg to 17.2 mg). All three are FDA-approved with published safety data, unlike retatrutide.

What's the only legal way to access retatrutide right now?

Enrollment in one of its registered clinical trials, such as NCT04881760, NCT05929066, or NCT05882045, is the only lawful access route today. There is no prescription pathway, no compounding pathway, and no approved commercial product outside those trial settings.

Is retatrutide being reviewed for the 503A Bulks List?

No. FDA's Pharmacy Compounding Advisory Committee reviewed seven other peptides in July 2026 (BPC-157, KPV, TB-500, MOTS-c, emideltide, semax, epitalon) for possible Bulks List inclusion. Retatrutide wasn't among them and has never been formally nominated for the list.

What's the difference between 503A and 503B for retatrutide?

503A governs compounding pharmacies making patient-specific prescriptions; 503B governs larger outsourcing facilities. Both have separate bulk substance lists (21 CFR 216.23 and 216.24 respectively), and retatrutide appears on neither, so no compounding route exists under either framework.

Sources

1. Drugs@FDA, FDA-approved drug products database: A search for the generic name retatrutide returns no approved product.
2. 21 CFR 216.23, eCFR: The final 503A Bulks List contains exactly six substances, none a peptide, and retatrutide is not among them.
3. 21 U.S.C. 353a(b)(1)(A)(i): Section 503A's cascade requires monograph compliance, approved-drug component status, or Bulks List presence before compounding, none of which retatrutide meets.
4. 21 U.S.C. 355: A new drug cannot be introduced into interstate commerce without an approved application.
5. Drugs@FDA, NDA 220934 overview: Orforglipron was approved as Foundayo under NDA 220934 in six strengths from 0.8 mg to 17.2 mg.
6. FDA, Bulk Drug Substances Used in Compounding Under Section 503A: FDA maintains a public list of nominated bulk substances with interim categories; retatrutide is not on it.
7. Federal Register, Docket FDA-2025-N-6895: FDA's Pharmacy Compounding Advisory Committee met in July 2026 to review seven peptides, not including retatrutide, for the Bulks List.
8. 21 CFR 201.128: Intended use is established by labeling claims, advertising, and seller statements, not by a disclaimer.
9. Jastreboff AM et al., New England Journal of Medicine, 2023: The 12 mg dose produced 24.2 percent mean weight reduction at 48 weeks versus 2.1 percent for placebo; retatrutide is a GIP/GLP-1/glucagon triple agonist.
10. ClinicalTrials.gov NCT04881760: The phase 2 obesity trial (LY3437943/retatrutide) is registered with dose arms, route, and related type 2 diabetes trials noted.
11. ClinicalTrials.gov NCT05929066: A later-phase retatrutide trial registration lists enrollment criteria, comparators, and endpoints.
12. ClinicalTrials.gov NCT05882045: A second later-phase retatrutide trial registration documents dosing and design under study.
13. 21 CFR 216.24: The separate 503B bulks list for outsourcing facilities also does not include retatrutide.
14. FDA, Personal Importation: FDA's personal importation policy is narrow and does not create a general pathway for buying unapproved drugs from overseas.
15. NIDDK, Weight Management: NIDDK publishes federal guidance on evidence-based weight management as a neutral reference point.